Multivariate analyses of progression-free survival
. | . | . | 95% CI for HR . | . | |
|---|---|---|---|---|---|
. | P . | HR . | Lower . | Upper . | |
| Clinical stage, extranodal disease and early interim FDG-PET | |||||
| Step 1 | |||||
| Clinical stage | .378 | 1.397 | 0.664 | 2.939 | |
| Extranodal disease | .346 | 2.018 | 0.469 | 8.678 | |
| PET2 (qualitative) | < .001 | 36.281 | 7.179 | 183.4 | |
| Step 2 | |||||
| Extranodal disease | .070 | 2.906 | 0.918 | 9.199 | |
| PET2 (qualitative) | < .001 | 36.887 | 7.338 | 185.4 | |
| Clinical stage, extranodal disease and SUVmax | |||||
| Step 1 | |||||
| Clinical stage | .550 | 1.280 | 0.570 | 2.872 | |
| Extranodal disease | .038 | 5.310 | 1.096 | 25.725 | |
| SUVmax | .105 | 1.071 | 0.986 | 1.164 | |
| Step 2 | |||||
| Extranodal disease | .017 | 6.046 | 1.382 | 26.453 | |
| SUVmax | .034 | 1.084 | 1.006 | 1.168 | |
. | . | . | 95% CI for HR . | . | |
|---|---|---|---|---|---|
. | P . | HR . | Lower . | Upper . | |
| Clinical stage, extranodal disease and early interim FDG-PET | |||||
| Step 1 | |||||
| Clinical stage | .378 | 1.397 | 0.664 | 2.939 | |
| Extranodal disease | .346 | 2.018 | 0.469 | 8.678 | |
| PET2 (qualitative) | < .001 | 36.281 | 7.179 | 183.4 | |
| Step 2 | |||||
| Extranodal disease | .070 | 2.906 | 0.918 | 9.199 | |
| PET2 (qualitative) | < .001 | 36.887 | 7.338 | 185.4 | |
| Clinical stage, extranodal disease and SUVmax | |||||
| Step 1 | |||||
| Clinical stage | .550 | 1.280 | 0.570 | 2.872 | |
| Extranodal disease | .038 | 5.310 | 1.096 | 25.725 | |
| SUVmax | .105 | 1.071 | 0.986 | 1.164 | |
| Step 2 | |||||
| Extranodal disease | .017 | 6.046 | 1.382 | 26.453 | |
| SUVmax | .034 | 1.084 | 1.006 | 1.168 | |
P indicates level of significance; HR, hazard ratio; and CI, confidence interval.